摘要
目的研究头孢哌酮/舒巴坦治疗重度慢性阻塞性肺疾病急性加重期的临床疗效。方法对136例重度慢性阻塞性肺疾病急性加重期患者随机分为头孢哌酮/舒巴坦治疗组和头孢他啶对照组,疗程均为7 d,治疗前后行痰培养。结果治疗组与对照组临床疗效、细菌清除率分别为91.18%、96.67%和70.59%、75.86%,两组临床疗效与细菌清除率差异均有统计学意义(P<0.05)。结论头孢哌酮/舒巴坦治疗重度慢性阻塞性肺疾病急性加重期效果好,可作为治疗重度慢性阻塞性肺疾病急性加重期患者的经验用药。
OBJECTIVE To evaluate the clinical efficacy of cefoperazone/sulbactam（Sulperazon） for acute exacerbation of chronic obstructive pulmonary disease（AECOPD）.METHODS A total of 136 cases of AECOPD were randomized into cefoperazone/sulbactam group and ceftazidime group,and sputum culture of each case was underwent before and after treatment.RESULTS The total efficacy rates and bacterial clearance rates in cefoperazone/sulbactam group and ceftazidime group were 91.18%,96.67% and 70.59%,75.86%,respectively,and the differences between the two groups were statistically significant.CONCLUSIONS It suggested that cefoperazone/sulbactam be a more effective drug for AECOPD.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2009年第24期3402-3403,共2页
Chinese Journal of Nosocomiology
关键词
重度慢性阻塞性肺疾病
急性加重期
头孢哌酮/舒巴坦
Severe chronic obstructive pulmonary disease
Acute exacerbation
Cefoperazone/sulbactam
